Long-Term Study of IGIV, 10% in Alzheimer´s Disease

This study has been terminated.
(The study was terminated because the first Phase 3 did not demonstrate efficacy on the co-primary endpoints. The known safety profile remained unchanged.)
Sponsor:
Information provided by (Responsible Party):
Baxalta US Inc.
ClinicalTrials.gov Identifier:
NCT01736579
First received: November 27, 2012
Last updated: July 13, 2016
Last verified: July 2016
  Purpose
The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701. Participants and investigators will be blinded to dose unless otherwise notified by the sponsor.

Condition Intervention Phase
Alzheimer´s Disease
Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease

Resource links provided by NLM:


Further study details as provided by Baxalta US Inc.:

Primary Outcome Measures:
  • Number and Severity of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Number of Infusions Temporally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Number of Infusions Causally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Number of Infusions Discontinued, Slowed or Interrupted Due to an Adverse Event (AE) or Serious Adverse Event (SAE) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Total Score of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at the site.

    Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment.


  • Total Score of the Cognitive Subscale of the Severe Impairment Battery (SIB) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The SIB is a 40-item psychometric assessment that is composed of simple one-step commands combined with gestures. The scoring range is from 0 to 100 with a lower score indicating greater cognitive impairment.

  • Alzheimer's Disease Cooperative Study (ADCS) - Activities of Daily Living (ADL) Inventory (ADCS-ADL/ ADCS-ADL-severe) [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.

    Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.


  • Mini Mental State Examination (MMSE) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The MMSE is a test for cognitive dysfunction. The test provides a 30-point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. The total score can range from 0 to 30 with a higher score indicating better function.

  • Neuropsychiatric Inventory (NPI) Score [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The NPI is a validated instrument used to assess behavioral psychopathology in Alzheimer's Disease; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.

  • Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The QOL-AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL-AD are associated with a lower quality of life.

  • EQ-5D Questionnaire (Proxy Version) [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.

    The EQ-5D also includes a standard vertical 20 cm visual analogue scale (VAS) ranging from best imaginable health state [100] to worst imaginable health state [0].

    Caregivers are asked to describe how they believe a participant would rate his/her health state that day.


  • Healthcare Resource Utilization Questionnaire (HRUQ) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The HRUQ determines if there is a difference in healthcare utilization and health-related expenditures, most notably nursing home (ie, skilled nursing facility) admissions, when subjects are treated with study product. This assessment is performed with the primary caregiver.

  • Caregiver Burden Questionnaire [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The Caregiver burden questionnaires is a self-administered questionnaire that has been developed to measure the emotional, physical, and social impact of caregiving on Alzheimer's Disease caregivers.

  • Time to Skilled Nursing Facility Placement [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Time to skilled nursing facility placement is defined as permanent admission to a skilled nursing facility. Time will be defined as the number of months between enrollment into this clinical study and placement in a skilled nursing facility placement.

  • Volumetric MRI [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Volumetric MRI measurements were obtained to assess rate of whole brain atrophy and ventricular enlargement. Additional volumetric measurements may be analyzed when specific hypotheses and methods are defined. Additional volumetric MRI analysis may include (but may not be limited to) one or more of the following: rate of hippocampal atrophy, entorhinal cortical thickness, and/or regional cortical thinning.


Enrollment: 6
Study Start Date: November 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IGIV, 10% at 0.2 g/kg body weight
IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.
Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Other Name: Gammagard Liquid
Experimental: IGIV, 10% at 0.4 g/kg body weight
IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months
Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Other Name: Gammagard Liquid

  Eligibility

Ages Eligible for Study:   51 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Completed 18 months of study treatment and assessments in Baxter precursor study 160701
  • Diagnosis of probable Alzheimer´s Disease (AD)
  • Able to comply with testing and infusion regimen (including adequate corrected visual acuity and hearing ability)
  • Has a caregiver (study partner) who is willing and able to participate

Main Exclusion Criteria:

  • Significant neurological disease other than AD
  • Clinically significant cardiac/cardiovascular problems (e.g. uncontrolled blood pressure, atrial fibrillation, heart disease, clotting disorders, strokes, or recent heart attack)
  • Contraindication to undergoing MRI (e.g. pacemaker [with the exception of an MRI-compatible pacemaker], severe claustrophobia, ferromagnetic implants such as a metal plate)
  • Specific findings on brain MRI (microhemorrhages, superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, or multiple lacunae)
  • Active malignancy or history of malignancy within 5 years prior to screening with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment
  • Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)
  • Poorly controlled diabetes
  • Serious problems with liver or kidneys
  • Known history of hypersensitivity following infusions of human blood or blood components (e.g. human immunoglobulins or human albumin)
  • Current or recent treatment with immunomodulatory therapies (with the exception of immunoglobulin and non-systemic and low-dose systemic corticosteroids)
  • Recent use of investigational drugs or biologics, including those aimed at altering AD progression (with the exception of immunoglobulin)
  • Active immunization for the treatment of AD at any time

There are reasons why it might not be appropriate to participate in this trial. Please contact Medical Information at medinfo@baxter.com for details.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01736579

Locations
United States, New York
Rochester, New York, United States
Sponsors and Collaborators
Baxalta US Inc.
Investigators
Study Director: David Gelmont, MD Baxalta US Inc.
  More Information

Responsible Party: Baxalta US Inc.
ClinicalTrials.gov Identifier: NCT01736579     History of Changes
Other Study ID Numbers: 161202 
Study First Received: November 27, 2012
Results First Received: July 13, 2016
Last Updated: July 13, 2016
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Immunoglobulins
Antibodies
Gamma-Globulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 22, 2016